1 International Program of Psycho-Social Health Research (IPP-SHR), Central Queensland University, Kenmore, Brisbane, Queensland, Australia 2 School of Medicine and Pharmacy, University of Western Australia, Fremantle, Western Australia, Australia 3 Department of Haematology, Fremantle Hospital, Fremantle, Western Australia, Australia.
Patient. 2009 Mar 1;2(1):19-31. doi: 10.2165/01312067-200902010-00003.
Corticosteroids are documented as associated with psychological adverse effects, including insomnia, irritability, aggression, neuropsychological deficits, mood disorders (including severe depression), delirium, and psychosis. Given the severity of these potential adverse effects and that corticosteroid use is central to the treatment of most hematological malignancies, it would be expected that a thorough research literature would exist on the effects of corticosteroid use in hematology. However, scant research is available. This leaves many questions unanswered and a vacuum for clinical practice. Thus, there is a strong need for empirical data, not only on the psychological adverse effects experienced by patients, but also on the coping strategies patients use to manage them.
To present findings on the coping strategies used by ten hematology patients in Australia undergoing treatment involving corticosteroids as a first step in understanding the emotional and psychological effects experienced by this group of patients.
The pilot study was conducted from January 2007 until March 2008.The study participants were ten hematology outpatients (eight with multiple myeloma, two with acute immune thrombocytopenia purpura) from two major Australian public hospitals (Princess Alexandra Hospital, Brisbane, Queensland, and Fremantle Hospital, Fremantle, Western Australia) who were taking dexamethasone and/or prednisolone and referred to the study by their treating hematologists on the basis that they were experiencing difficulties with their corticosteroid therapy.Data were collected through an iterative, phenomenological, qualitative research methodology using open-ended interviews. Interview transcriptions were entered into the QSR NUD*IST (Non-numeric, Unstructured Data * Index and Searching Technology) computer program and analyzed thematically.
Coping strategies found to be helpful by patients included believing that corticosteroids are necessary for disease control, knowing that the negative emotional states being experienced are due to the corticosteroids, stoicism and self-reliance based on a cognitive-rational approach, keeping busy, remaining fit and active, and, for some, using antidepressants to help with mood swings. For sleep disturbances, patients found it helpful to try to accept the sleeplessness, engage in distraction, and have light sleeps. Support from family and friends who understand the range of corticosteroid adverse effects, including patients' need to withdraw during treatment, was seen as important. Counseling was not considered helpful. Tapering corticosteroid doses and cessation of corticosteroids were also discussed as aids to coping.
These findings provide a start to understanding how individuals cope with corticosteroid therapy for hematological conditions. There is a need for further extensive research in this area.
皮质类固醇已被证明与心理不良反应有关,包括失眠、易怒、攻击性、神经心理缺陷、情绪障碍(包括严重抑郁)、谵妄和精神病。鉴于这些潜在不良反应的严重程度,以及皮质类固醇的使用是治疗大多数血液恶性肿瘤的核心,人们预计会有大量关于血液学中皮质类固醇使用效果的研究文献。然而,可用的研究很少。这使得许多问题没有答案,也没有临床实践的空白。因此,不仅需要关于患者所经历的心理不良反应的实证数据,还需要关于患者用来管理这些不良反应的应对策略的实证数据。
介绍澳大利亚十名接受皮质类固醇治疗的血液科患者使用的应对策略,这是了解该组患者所经历的情绪和心理影响的第一步。
该初步研究于 2007 年 1 月至 2008 年 3 月进行。研究参与者是来自澳大利亚两家主要公立医院(昆士兰州布里斯班的亚历山德拉公主医院和西澳大利亚州弗里曼特尔的弗里曼特尔医院)的十名血液科门诊患者(八名多发性骨髓瘤患者,两名急性免疫性血小板减少性紫癜患者),他们正在服用地塞米松和/或泼尼松龙,并由他们的治疗血液科医生转介给该研究,因为他们在皮质类固醇治疗方面遇到困难。通过迭代的、现象学的、定性研究方法收集数据,使用开放式访谈。访谈转录被输入 QSR NUDIST(非数字、非结构化数据索引和搜索技术)计算机程序,并进行主题分析。
患者发现有用的应对策略包括相信皮质类固醇对疾病控制是必要的、知道正在经历的负面情绪状态是由于皮质类固醇、基于认知-理性方法的坚忍和自力更生、保持忙碌、保持健康和活跃、以及对于一些人来说,使用抗抑郁药来帮助控制情绪波动。对于睡眠障碍,患者发现尝试接受失眠、分散注意力和浅睡眠是有帮助的。理解皮质类固醇不良反应范围的家人和朋友的支持,包括患者在治疗期间需要退出,被认为很重要。咨询被认为没有帮助。逐渐减少皮质类固醇剂量和停止使用皮质类固醇也被认为是应对的辅助手段。
这些发现为了解个体如何应对血液疾病的皮质类固醇治疗提供了一个起点。需要在这一领域进行进一步的广泛研究。